Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Li, Yanyan; 1 | Ma, Xuelei; 1 | Zhao, Jingyi; 1 | Zhang, Binglan | Jing, Zhang | Liu, Lei; *
Affiliations: Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China
Correspondence: [*] Corresponding author: Dr. Lei Liu, Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. Tel.: +86 28 85164060; Fax: +86 28 85164060; E-mail: liuleihx@gmail.com.
Note: [1] These authors contributed equally to this work.
Abstract: Background:microRNA-210 expression in breast carcinoma represents an appealing prognostic tool, but no consensus exists on this debating topic. Objective:We conducted this comprehensive meta-analysis to summarize evidence for use of microRNA-210 to predict patients’ clinical outcomes. Methods:Relevant literatures were identified using Pubmed and EMBASE. Patients’ clinical characteristics and survival related data were extracted. Statistics extracted from Kaplan–Meier survival curves were calculated with methods developed by Parmar, Williamson, and Tierney, multivariate Cox hazard regression analysis data were used directly in Revman 5.0. Pooled hazard ratios (HRs) were calculated to evaluate the prognostic role of microRNA-210. Results:Finally, 7 studies containing 822 patients were considered eligible, pooled HR (95% CI) of studies for overall survival was 3.94 (1.90–8.15), for disease/recurrence free survival was 3.47 (2.63–4.60) and for metastasis free survival was 2.70 (1.46–5.00). We then respectively grouped the meta-analysis by patients’ region (Asia and non-Asia), tumor estrogen receptor/ progesterone receptor/Her-2 expression status (positive or negative) and treatment strategy (preoperative systemic treatment or only surgery). All the subgroup analysis showed stable prognostic value. Conclusions:Over-expressed microRNA-210 demonstrated a significantly higher risk of recurrence, metastasis and overall decreased survival rates for breast cancer patients.
Keywords: microRNA-210, breast cancer, prognostic factor, meta-analysis
DOI: 10.3233/CBM-130385
Journal: Cancer Biomarkers, vol. 13, no. 6, pp. 471-481, 2013
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl